Livzon Pharmaceutical Group Inc.

Symbol: 000513.SZ

SHZ

39.5

CNY

company-market-status

  • 19.0666

    P/E ratio

  • 4.9846

    PEG ratio

  • 32.60B

    Mrk Cap

  • 0.03%

    Div Yield

Акции в обращение

825.393002M

Притежавани от вътрешни лица

0.033%

Притежавани от институции

3.302%

  • Highest
    • 34.45
    • 30.52
    • 22.88
    • 21.07
    • 16.99
    • 18.95
    • 22.95
    • 24.30
    • 23.06
    • 23.38
    • 23.11
    • 24.14
    • 28.70
    • 30.65
    • 36.08
    • 36.18
    • 37.38
    • 45.47
    • 50.92
    • 46.07
    • 40.87
    • 37.92
    • 34.03
    • 35.44
    • 40.21
    • 49.17
    • 49.16
    • 39.22
    • 34.18
    • 34.67
    • 33.72
    • 36.93
    • 37.07
    • 32.96
    • 36.29
    • 31.95
    • 31.38
    • 37.17
    • 38.79
    • 34.21
    • 35.95
  • Lowest
    • 32.74
    • 29.44
    • 22.88
    • 19.49
    • 16.99
    • 18.29
    • 22.31
    • 23.67
    • 23.06
    • 22.64
    • 22.77
    • 24.14
    • 26.47
    • 30.65
    • 35.33
    • 36.18
    • 36.38
    • 43.50
    • 49.06
    • 46.07
    • 39.79
    • 37.92
    • 32.56
    • 34.60
    • 38.48
    • 45.13
    • 47.34
    • 37.09
    • 33.32
    • 34.19
    • 33.72
    • 36.01
    • 35.95
    • 32.00
    • 35.63
    • 31.38
    • 30.68
    • 34.65
    • 37.08
    • 33.88
    • 35.43

Информация за компанията

Последващ PE: Healthcare
Индустрия: Drug Manufacturers—Specialty & Generic
ГЛАВЕН ИЗПЪЛНИТЕЛЕН ДИРЕКТОР:Mr. Yanggang Tang
Служители на пълно работно време:9005
Град:Zhuhai
Адрес:Headquarters Building
IPO:1993-10-28
CIK:

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.

Оборотен капитал

202220212020201920182017
Парични средства и инвестиции10411.359146.379953.758855.418587.937415.78
Приемници0.000.000.000.000.000.00
Инвентарна книга2045.341663.231487.801168.851117.011102.62
Други136.9057.9451.28128.282750.862822.73
Общо текущи активи16987.3014673.1014627.3612873.2012471.7311349.87
Acc Payable1862.021817.301624.791263.091354.911163.53
Краткосрочен дълг1632.682052.331559.481360.841500.400.40
Други текущи пасиви3901.963055.442898.612669.732269.212201.35
Текущи пасиви7396.666925.076082.895293.665369.584411.03

Капиталова структура

Всички числа в милиони

Общо активи

1856,44 щ.д.

Общо задължения

727051914,41 щ.д.

Дългосрочен дълг

71,50 щ.д.

Парични средства и екви

295276726,93 щ.д.

Goodwill

0,00 щ.д.

Неразпределена печалба

16165850,12 щ.д.

Обикновени акции

935,55 щ.д.

Стойност на предприятието

15,04 щ.д.

Дивиденти за маса

ГодиниQ1Q2Q3Q4Общо
19950.0000.0000.0770.0000.077
19960.0000.0000.0510.0000.051
19990.0000.0000.0160.0000.016
20020.0000.0000.0100.0000.010
20030.0000.0320.0000.0000.032
20040.0000.0320.0000.0000.032
20050.0000.0000.0480.0000.048
20080.0000.1750.0000.0000.175
20090.0000.0350.0000.0000.035
20100.0000.0530.0000.0000.053
20110.0000.0350.0000.0000.035
20120.0000.1750.0000.0000.175
20130.0000.0000.1750.0000.175
20140.0000.0000.1750.0000.175
20150.0000.0000.0350.0000.035
20160.0000.2280.0000.0000.228
20170.0000.0000.2280.0000.228
20180.0001.1830.0000.0001.183
20190.0000.0000.9230.0000.923
20200.0001.1500.0000.0001.150
20210.0001.2500.0000.0001.250
20220.0001.3000.0000.0001.300
Подобни запаси
Може да се интересувате и от
PILL.CN
Canntab Therapeutics Limited.
0.01 CAD
CNQ
CRON
Cronos Group Inc..
1.77 USD
NASDAQ
RMTI
Rockwell Medical, Inc..
2.39 USD
NASDAQ
ATNX
Athenex, Inc..
0.2031 USD
NASDAQ
SCYX
SCYNEXIS, Inc..
2.64 USD
NASDAQ
RDHL
RedHill Biopharma Ltd..
2.2 USD
NASDAQ
CPIX
Cumberland Pharmaceuticals Inc..
1.585 USD
NASDAQ
PRPH
ProPhase Labs, Inc..
9.78 USD
NASDAQ
OGI
OrganiGram Holdings Inc..
0.4419 USD
NASDAQ
BOI.PA
Boiron SA.
39 EUR
EURONEXT

Frequently Asked Question

Why is your stock tool better than competitors?

Numfin provides most features for free and gives you accurate and expert data about public companies. We also offer unique features like AI copilot that are not found on other platforms

Can I trust the data on your website and where do they come from?

Absolutely. We receive the data from our partners and other official sources, such as popular stock exchanges (NASDAQ, NYSE, and others), SEC.gov, and other official platforms. Our data provider, FinancialModeling, also provides information for portals like Moody's, Harvard, Chevron, and others. All this proves the accuracy and authority of the information.

Who creates the content on your website and is it approved by experts in finance and investing?

All financial data is received from our data provider and then verified by industry experts. Additionally, we use various AI tools like ChatGPT to present content in a user-friendly and well-structured manner.

What problem does your tool solve? Who is the target audience for your tool

Our main goal is to present accurate and expert information about public companies in a structured manner. We work with investors and financial professionals who have a long-term outlook. Our community consists of private investors, business owners, stock analysts, fund managers, and people who are interested in investing.

Why did you decide to create your tool?

While managing our own money, we searched for the best analytical tool to help us better analyze public companies. Most websites that provided analytics for professional investors were expensive, and the cheap tools were either limited in functionality or lacked valuable company data. Even worse, some of them presented incorrect numbers. As a result, we combined our experience in business, IT, and finance to create the most affordable and useful solution for investors and anyone interested in finance and stock analysis.

What is the difference between free and paid options? Should I buy Pro version from start or it's ok to have a free version?

Most features on our website are free so that many people can use it to analyze companies on the world's top stock exchanges. However, some features, such as our artificial intelligence chat, advanced analytics, filters, and storing of vast historical data, require additional servers from our end. Therefore, we rely on your support to keep this amazing project running. If you would like to experience the full potential of our service, we strongly recommend that you purchase the PRO version, which comes with a 30-day money-back guarantee

Who is your team and do they have enough experience?

You can read about our team here, or you can contact us at [email protected] for more information.